50 Most Innovative Companies to Watch 2021
The Healthcare sector is one of the most critical sectors that impact the entire global population and is closely linked to the development of any country. It also plays a crucial role in how a country is perceived in maintaining economic stability. But sadly, even after the continuous evolution of the industry, accessibility remains a key challenge. At least half of the world’s population does not have access to the health services they need, which is an alarmingly high rate, mainly as this is a sector that impacts most people at some point in their life.
JB Consulting (MDP) Limited is a company dedicated to providing Pharmaceutical Medical Consultancy Services in the United Kingdom and Nigeria. Apart from this, it also has tie-ups with some of the major recognized organizations in the United Kingdom, including Astellas Pharma, Daiichi-Sankyo, Napp Pharmaceuticals, etc. We interviewed John Bolodeoku, the Founder of JB Consulting MDP, to understand more about the company and its services. Here are a few excerpts of the same:
Q. How do you deal with the rising consumer expectations and difficulties managing brand health?
The understanding of consumer expectations is very crucial to the survival of any brand. Therefore, the two go hand in hand. It is essential to be flexible as best as it is possible within the brand to keep up with rising expectations while still remaining true to the brand.
Q. Pharmaceutical fraud remains to be a major challenge for the industry¬, possibly even worse during COVID-19. What is your take on this?
Pharmaceutical fraud and mistrust are challenges that the Pharmaceutical Industry will always have to contend with. The pharmaceutical industry has the responsibility to continue to demonstrate that it can address fraud and mistrust by adhering to and complying with the regulatory infrastructure in place to address both fraud and mistrust.
Q. How challenging was being a consultant in accessing diagnostic pathology services?
The challenge has been reasonable, but a solid foundation experience in Chemical Pathology and Molecular Pathology provides the company with the ability to understand biochemical and molecular laboratory tests used to diagnose disease and to manage patients. With further experience in the pharmaceutical industry, we play a significant part in making JB Consulting navigate the field of diagnostic pathology, which is quite broad.
Q. How do you assist a variety of pharmaceutical companies?
We have gained experience working for Contract Research Organisations (CROs), small, medium, and large pharmaceutical companies, in both operational and strategic positions. We also cover broad therapeutic areas. In addition, to working as a practicing physician in collaboration with the pharma on projects, JB Consulting MDP Ltd can support pharma, diagnostic, and device companies in the development of new medicines, diagnostic tests, and devices for patients benefit, which includes:
Q. What is your marketing and distribution strategy?
JB Consulting MDP aims to focus its marketing and distribution on developing point-of-care testing (POCT) with diagnostic devices incorporating digital smartphones and artificial intelligence evolution.
Q. What accolades did you receive for your achievements?
In the last couple of years, JB Consulting MDP has received a couple of awards:
Q. Do you have any plans of expanding the firm? If yes, share some details.
I would like to explore developing the interactions between Pharma and Diagnostic companies as to how both industries can bring together solutions to the healthcare community and its patients.
Meet the Founder
John Bolodeoku is the Founder of JB Consulting MDP Limited. He is a Chemical Pathologist and Pharmaceutical Medicine Physician who graduated from the University of Ibadan, MBBS, in 1986. John has held several positions and provided services in Clinical Research and Medical Affairs for several pharmaceutical companies (full time and interim) in the UK and Europe: BIOS (Consultancy & Research Organization), Pfizer, Yamanouchi, Astellas, Teva, Daichii Sankyo, Biogen Idec, Roche, NAPP, ICON Solutions, Eli Lilly, Celgene, and Novartis.
Over the years, he has worked with several diagnostic device manufacturers on a number of devices, mainly in the area of point of care testing (POCT) and self-testing and monitoring in diabetes, cholesterol, general chemistry, and a wide range of immunoassays. John has two masters degrees, one in Clinical Biochemistry (University of London) and another one in Business Administration (University of Liverpool), a doctorate in Molecular Pathology (University of Oxford), and is a Fellow of the Royal College of Pathology and the Royal Society of Biology. In addition, he is a Senior Lecturer at Kings College, London. John is the joint author of a textbook in Pathology titled “Pathology Integrated” and has over 80 publications and abstracts. Currently, he provides consultancy services to laboratories, pharmaceutical, and diagnostic device companies working as part-time CMO and Clinical Director to a number of SMEs. He has a passion for “bringing diagnostics closer to the patients” and integrating, diagnostics, devices and pharmaceuticals.